The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO

In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA. But Emily Leproust and her co-founders saw something different. They saw "a big market with unhappy customers.” Today, with a radically disruptive technology, they are market dominant. Twist is a publicly traded company whose stock has doubled already once since they IPOd last year. Imagine, a DNA synthesis company going public! And then seeing their stock perform so well. This is tricky for the most hyped of tech or biotech startups.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe